secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2024-08-20T23:59:59+00:00
Accession:  0001493152-24-033265
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem and Aditxt amend merger, extend third equity investment deadline contingent on Aditxt raising $20M
--------------------------------------------------------------------------------

- Third Parent Equity Investment deadline moved to earlier of Sep 6, 2024 or 5 business days after Aditxt closes a ≥$20M public offering.
- Aditxt must purchase 2,000 shares of Evofem Series F-1 Preferred for $2,000,000 on that date.
- Other investment dates unchanged: $500k (Jul 12), $500k (Aug 9), $1,000k (Sep 30).
- Amendment signed Aug 16, 2024 by CEOs of Evofem (Saundra Pelletier) and Aditxt (Amro Albanna).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224033265/0001493152-24-033265-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224033265/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-033265

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer